Clinical Trials Browser

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT04734730 2026-01-28

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Phase 2 Recruiting

70 enrolled

Genitourinary

Prostatic Neoplasms

NCT05873192 2025-12-23

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Phase 2 Recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT06844383 2025-10-29

TALENT

Phase 2 Recruiting

126 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04678362 2025-09-22

TALASUR

Phase 2 Recruiting

50 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04486352 2025-09-04

EndoMAP

Phase 1/2 Recruiting

148 enrolled

Gynecologic

Endometrial Neoplasms

NCT03990896 2025-08-07

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms

NCT05035745 2025-07-25

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Phase 1/2 Recruiting

63 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05071937 2025-06-22

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Phase 2 Recruiting

33 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05101551 2025-05-29

PARPAML

Phase 1 Recruiting

34 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04892693 2025-04-17

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Phase 2 Recruiting

70 enrolled

Breast

Advanced Breast Cancer

NCT06193525 2025-02-28

FUTURE

Phase 2 Recruiting

66 enrolled

Breast

Breast Neoplasms

NCT05053854 2025-02-20

PARLuNET

Phase 1 Recruiting

24 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT04819243 2025-01-03

Young-PALETTA

Phase 2 Recruiting

178 enrolled

Breast

Premenopausal HR+/HER2- Metastatic Breast Cancer

NCT06218628 2024-05-03

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Phase 1 Recruiting

24 enrolled

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

TAPUR

I-SPY

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Talazoparib

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

TALENT

TALASUR

EndoMAP

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

PARPAML

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

FUTURE

PARLuNET

Young-PALETTA

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

EVIDENT